• Most Popular
  • Most Shared

UPDATE 1-ViroPharma ends development of hepatitis C drug

Wed Apr 16, 2008 6:34pm EDT

Stocks

   

(Recasts, adds details)

Stocks

April 16 (Reuters) - ViroPharma Inc (VPHM.O) said it discontinued the development of its experimental hepatitis C drug due to safety concerns.

ViroPharma, which was developing the drug, HCV-796, with Wyeth WYE.N, said it does not expect to continue to collaborate with Wyeth on future development of hepatitis C treatment candidates.

The company said the risk associated with potential liver toxicity posed too high a hurdle to merit further development of the drug.

ViroPharma halted the mid-stage trial of HCV-796 in August 2007 after some patients developed elevated liver enzymes, a warning signal for liver damage.

ViroPharma shares, which closed at $9.62 Wednesday on Nasdaq, fell 6 percent to $9.05 in trading after the bell. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Vinu Pilakkott)

Stocks


More from Reuters

Joint Terminal Attack Controller SSgt Clinton J. Herbison, a U.S. Airman from the 817 Expeditionary Air Support Operations Squadron (EASOS) takes a break during a night mission near Honaker Miracle camp at the Pesh valley of Kunar Province August 12, 2009. Credit: REUTERS/Carlos Barria

Pictures of the Year

A look at the best photos of 2009.  Slideshow 

    PICTURES
    The Dalai Lama jokes with a nasal spray after being asked his opinion on the swine flu during a press conference after his first lecture in Lausanne, Switzerland, August 4, 2009. REUTERS/ Valentin Flauraud

    What a wacky year it's been...

    Um, what's up the Dalai Lama's nose? "Oddly Enough" editor Bob Basler rounds up the goofiest photos of the year.  Full Article 

    Oddly Enough
    A caution sign is seen next to a stock board at the Australian Securities Exchange (ASX) in Sydney September 5, 2008. REUTERS/Daniel Munoz
    Political Risk in 2010:

    Don't say we didn't warn you

    With the financial crisis (mostly) in the past, U.S. investors are eying a fresh start to the coming year. Here's a look at what speedbumps lie ahead.  Full Article 

    Global Markets